Is Hormone Replacement Therapy Safe?

Something has shifted. Your sleep is off, your energy is not what it was, and you do not quite feel like yourself anymore. Someone mentioned hormone replacement therapy, and now you are trying to figure out if it is actually safe.

It is a fair question, and you deserve a real answer — not a dismissal, and not a fear-based response rooted in research that is two decades old and was never designed to answer it for someone like you. For most healthy women experiencing perimenopausal or menopausal symptoms, the current evidence supports hormone therapy as a safe and effective option. What matters is timing, formulation, and working with a provider who understands how all of it applies to your specific situation.

Here is what the science actually says.

In 2002, a large federally funded trial called the Women’s Health Initiative was halted early after researchers identified elevated rates of breast cancer, heart disease, and stroke in women taking a specific combination of hormones. The Women’s Health Initiative enrolled postmenopausal women with an average age of 63, many of whom were more than a decade past their last menstrual period. The hormone formulation used was conjugated equine estrogen combined with medroxyprogesterone acetate, a synthetic progestin. This combination is very different from the formulations used in modern hormone replacement therapy, particularly bioidentical approaches that use hormones structurally identical to those the body produces.

A reanalysis of the WHI data, published in the Journal of the American Medical Association in 2017, found that women who began hormone therapy within ten years of menopause onset or before age 60 had a significantly different risk profile than the older women who comprised most of the original study. For this group, which more closely represents the women actually seeking hormone therapy today, the cardiovascular risks seen in the original study did not apply, and all-cause mortality was lower in women who received hormone therapy than in those who received placebo.

The principle that emerged from this and subsequent research is called the timing hypothesis: the effects of hormone therapy on the body depend substantially on when therapy begins relative to menopause onset. Starting early in the transition, when blood vessel function is still healthy and responsive to estrogen, produces different outcomes than starting a decade later.

The answer from current evidence is: sooner is generally better than later, for women without contraindications. The window of greatest benefit and lowest risk is within ten years of menopause onset or before age 60. Starting earlier in the transition preserves the cardiovascular and neurological benefits of estrogen support and avoids the adverse effects associated with initiating therapy in older, more estrogen-deprived tissue. If you have been waiting because you are not sure whether it is the right time, that hesitation may actually be working against you.

The documented benefits of hormone therapy for women extend well beyond symptom relief — though symptom relief alone represents a significant quality-of-life argument for many women. The evidence supports effects on bone density, cardiovascular health, cognitive function, urogenital tissue health, and overall mortality in appropriately selected patients.

Estrogen plays a direct role in bone remodeling. Its decline after menopause accelerates bone loss, and postmenopausal osteoporosis is one of the leading causes of disability and mortality in older women. Hormone therapy is one of the most effective interventions available for preserving bone density and reducing fracture risk. A 2023 analysis in the New England Journal of Medicine of long-term WHI follow-up data found that women who received hormone therapy had significantly lower rates of hip fracture compared to those who received placebo, with the protective effect persisting for years after therapy ended.

Estrogen receptors are distributed throughout the brain, including in regions associated with memory and executive function. The Kronos Early Estrogen Prevention Study found that women who began hormone therapy within six years of menopause showed preserved white matter integrity on brain imaging compared to placebo — a structural difference with implications for long-term cognitive health. The same study did not find this protective effect in women who began therapy more than ten years after menopause, consistent with the timing hypothesis.

Genitourinary syndrome of menopause — vaginal dryness, urinary urgency, recurrent urinary tract infections, pain with intercourse — is one of the most undertreated conditions in women’s health. Unlike hot flashes, which often resolve over time, urogenital symptoms tend to progress without treatment. Local vaginal estrogen, which delivers hormone directly to the tissue with minimal systemic absorption, is highly effective and carries a favorable safety profile even for women who are not candidates for systemic hormone therapy.

Hormone therapy is not appropriate for everyone, and an honest conversation about candidacy is part of responsible prescribing. Women with a personal history of hormone-receptor-positive breast cancer, active blood clot disorders, unexplained vaginal bleeding, or active liver disease are generally not candidates for systemic hormone therapy. Women with a history of cardiovascular disease may be candidates for transdermal therapy with careful evaluation.

For the majority of healthy women experiencing significant perimenopausal or menopausal symptoms, the benefit-to-risk analysis has shifted considerably since 2002. The North American Menopause Society’s 2022 position statement concluded that for women under 60 or within ten years of menopause, hormone therapy has a favorable benefit-risk profile and should not be withheld based on concerns derived from the original WHI interpretation.

The decision to begin hormone therapy is individual. It depends on your symptom burden, your personal and family health history, your values around quality of life, and having a provider who can evaluate all of those variables together. What it should not depend on is fear generated by research that did not apply to most of the women it was used to counsel.

The story of hormone replacement therapy over the past two decades is, in many ways, a story about how quickly a complex clinical picture can be flattened into a headline — and how long it takes for the nuance to catch up. Millions of women spent years without access to treatments that could meaningfully improve their health and quality of life because the clinical conversation never moved past a 2002 study that did not reflect them.

The women who have the best outcomes with hormone therapy are those who work with a provider who understands the full landscape of current evidence, individualizes the formulation and route of administration to their specific situation, and monitors and adjusts over time. That is exactly the approach we take at Bloom. Our integrative primary care and direct primary care model gives us the time and relationship to do that work properly in a relationship grounded in who you are and what the evidence actually says for your situation.

If you have been told HRT is not safe, or that you are not a candidate, or simply that your symptoms are something you have to live with, we would like to talk with you about what the current picture actually looks like.